Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma

Transformed indolent non-Hodgkin lymphoma (tiNHL) has historically been associated with poor outcomes, particularly for patients with relapsed or refractory (R/R) disease. Although chimeric antigen receptor (CAR) T-cell therapy has improved prognosis, many patients lack access or experience relapse following treatment, highlighting the need for additional therapeutic strategies. CD3×CD20 bispecific antibodies (BsAbs) are active in R/R large B-cell lymphoma (LBCL), though data in tiNHL are limited. Here, we report the efficacy and safety of epcoritamab and glofitamab in patients with R/R tiNHL (N = 74) compared with those of patients with R/R de novo diffuse LBCL (DLBCL; N = 166) from 9 academic centers in the Collaborative US Bispecifics Consortium (CUBIC). With a median follow-up of 11.5 months, best overall response rate (ORR) and complete response rate (CRR) were comparable in tiNHL (50%/31%) vs de novo DLBCL (51%/34%). 12-month progression-free survival was 25% (95% confidence interval [CI], 15-39) for tiNHL vs 34% (95% CI, 27-43) for de novo DLBCL (HR, 1.15 [95% CI, 0.83-1.61]) and 12-month overall survival was 38% (95% CI, 26-55) for tiNHL vs 47% (95% CI, 39-56) for de novo DLBCL (HR, 1.08 [95% CI, 0.73-1.60]). No differences in toxicity were observed. Similar findings were found via a 1:1 propensity score matching statistical approach. In conclusion, our study revealed comparable efficacy and toxicity of BsAbs for patients with R/R tiNHL vs patients with R/R de novo DLBCL, supporting their use in this patient population.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-11-19
DOI
https://doi.org/10.3324/haematol.2026.301578
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma

Andrew Philip Jallouk, Geoffrey Shouse, Robert Allyn Redd, Yazeed Sawalha et al.
Haematologica
Lymphoma Diagnosis and Treatment
article

Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma

Andrew Philip Jallouk, Geoffrey Shouse, Robert Allyn Redd, Yazeed Sawalha, Alex Francisco Herrera, Steven Michael Bair, Shakthi Bhaskar, Allison Marie Bock, Wendy Dixon, Philippe A. Armand, Karan L. Chohan, Scott J. Rodig, Amy A. Ayers, Reid W. Merryman, Ajay Major, Christopher R. Flowers, Ayushi Chauhan, Narendranath Epperla, Gilles Andre Salles, Sonia Godbole, Jennifer Leigh Crombie, Matthew Alexander Lunning, Lorenzo Falchi, Swetha Kambhampati Thiruvengadam, Aaron Zou, Pierre Stephan, Sairah Ahmed, Alexey V. Danilov
article en

Abstract

Transformed indolent non-Hodgkin lymphoma (tiNHL) has historically been associated with poor outcomes, particularly for patients with relapsed or refractory (R/R) disease. Although chimeric antigen receptor (CAR) T-cell therapy has improved prognosis, many patients lack access or experience relapse following treatment, highlighting the need for additional therapeutic strategies. CD3×CD20 bispecific antibodies (BsAbs) are active in R/R large B-cell lymphoma (LBCL), though data in tiNHL are limited. Here, we report the efficacy and safety of epcoritamab and glofitamab in patients with R/R tiNHL (N = 74) compared with those of patients with R/R de novo diffuse LBCL (DLBCL; N = 166) from 9 academic centers in the Collaborative US Bispecifics Consortium (CUBIC). With a median follow-up of 11.5 months, best overall response rate (ORR) and complete response rate (CRR) were comparable in tiNHL (50%/31%) vs de novo DLBCL (51%/34%). 12-month progression-free survival was 25% (95% confidence interval [CI], 15-39) for tiNHL vs 34% (95% CI, 27-43) for de novo DLBCL (HR, 1.15 [95% CI, 0.83-1.61]) and 12-month overall survival was 38% (95% CI, 26-55) for tiNHL vs 47% (95% CI, 39-56) for de novo DLBCL (HR, 1.08 [95% CI, 0.73-1.60]). No differences in toxicity were observed. Similar findings were found via a 1:1 propensity score matching statistical approach. In conclusion, our study revealed comparable efficacy and toxicity of BsAbs for patients with R/R tiNHL vs patients with R/R de novo DLBCL, supporting their use in this patient population.

Haematologica
Brigham and Women's Hospital (US), City Of Hope National Medical Center (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), University of Utah (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Huntsman Cancer Institute (US), The Ohio State University Wexner Medical Center (US), Assistance Publique – Hôpitaux de Paris (FR), City of Hope (US), Dana-Farber Cancer Institute (US), University of Colorado Cancer Center (US), Hôpital Saint-Louis (FR), Dana-Farber Brigham Cancer Center (US), Fred and Pamela Buffett Cancer Center (US), University of Nebraska Medical Center (US), Vanderbilt University Medical Center (US)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon